title: 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.
abstract: STAT3 is persistently activated and contributes to malignant progression in various cancers. Janus activated kinases (JAK) phosphorylate STAT3 in response to stimulation by cytokines or growth factors. The STAT3 signaling pathway has been validated as a promising target for development of anticancer therapeutics. Small-molecule inhibitors of JAK/STAT3 signaling represent potential molecular-targeted cancer therapeutic agents. In this study, we investigated the role of JAK/STAT3 signaling in 6-bromoindirubin-3'-oxime (6BIO)-mediated growth inhibition of human melanoma cells and assessed 6BIO as a potential anticancer drug candidate. We found that 6BIO is a pan-JAK inhibitor that induces apoptosis of human melanoma cells. 6BIO directly inhibited JAK-family kinase activity, both in vitro and in cancer cells. Apoptosis of human melanoma cells induced by 6BIO was associated with reduced phosphorylation of JAKs and STAT3 in both dose- and time-dependent manners. Consistent with inhibition of STAT3 signaling, expression of the antiapoptotic protein Mcl-1 was downregulated. In contrast to the decreased levels of phosphorylation of JAKs and STAT3, phosphorylation levels of the Akt and mitogen-activated protein kinase (MAPK) signaling proteins were not inhibited in cells treated with 6BIO. Importantly, 6BIO suppressed tumor growth in vivo with low toxicity in a mouse xenograft model of melanoma. Taken together, these results show that 6BIO is a novel pan-JAK inhibitor that can selectively inhibit STAT3 signaling and induces tumor cell apoptosis. Our findings support further development of 6BIO as a potential anticancer therapeutic agent that targets JAK/STAT3 signaling in tumor cells.
authors: Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
authors: Lucy
authors: L
authors: Liu
authors: Sangkil
authors: S
authors: Nam
authors: Yan
authors: Y
authors: Tian
authors: Fan
authors: F
authors: Yang
authors: Jun
authors: J
authors: Wu
authors: Yan
authors: Y
authors: Wang
authors: Anna
authors: A
authors: Scuto
authors: Panos
authors: P
authors: Polychronopoulos
authors: Prokopios
authors: P
authors: Magiatis
authors: Leandros
authors: L
authors: Skaltsounis
authors: Richard
authors: R
authors: Jove
references: Cell. 2002 Apr;109 Suppl:S121-31
references: 11983158
references: J Biol Chem. 1999 Nov 5;274(45):32507-11
references: 10542297
references: Cancer Metastasis Rev. 2005 Jun;24(2):315-27
references: 15986140
references: J Biol Chem. 2000 Aug 11;275(32):24935-44
references: 10823829
references: Hematology Am Soc Hematol Educ Program. 2009;:636-42
references: 20008249
references: Immunol Rev. 2008 Jun;223:132-42
references: 18613833
references: Gene. 2002 Feb 20;285(1-2):1-24
references: 12039028
references: Ann N Y Acad Sci. 2005 Nov;1059:16-25
references: 16382039
references: Nat Cell Biol. 1999 May;1(1):60-7
references: 10559866
references: Cancer Res. 2003 Mar 15;63(6):1270-9
references: 12649187
references: J Med Chem. 2006 Jul 27;49(15):4638-49
references: 16854069
references: Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5998-6003
references: 15837920
references: Nat Rev Cancer. 2004 Feb;4(2):97-105
references: 14964307
references: Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4288-93
references: 16857804
references: J Cancer Res Clin Oncol. 2004 Nov;130(11):627-35
references: 15340840
references: Leuk Lymphoma. 2002 Sep;43(9):1763-8
references: 12685829
references: Immunol Rev. 2009 Mar;228(1):273-87
references: 19290934
references: Oncogene. 2006 Oct 12;25(47):6304-18
references: 16702956
references: Cancer Cell. 2009 Dec 8;16(6):487-97
references: 19962667
references: Biochem Pharmacol. 2008 Jul 1;76(1):39-52
references: 18485331
references: J Biol Chem. 2001 Jan 5;276(1):251-60
references: 11013232
references: J Med Chem. 2004 Feb 12;47(4):935-46
references: 14761195
references: Curr Oncol Rep. 2009 Mar;11(2):117-24
references: 19216843
references: Nat Rev Cancer. 2009 Nov;9(11):798-809
references: 19851315
references: Cancer Cell. 2008 Apr;13(4):311-20
references: 18394554
references: Nat Rev Cancer. 2007 Sep;7(9):673-83
references: 17721432
references: Sci STKE. 2006 Jul 11;2006(343):pe30
references: 16835434
references: Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5
references: 15781862
references: Int J Clin Pharmacol Ther. 2005 Dec;43(12):592-4
references: 16372530
references: Oncogene. 2005 May 5;24(20):3236-45
references: 15735720
references: Cancer Res. 2009 Sep 15;69(18):7302-10
references: 19706767
references: Mol Cell Biol. 1997 Feb;17(2):695-706
references: 9001223
references: Mol Cell Biol. 1997 May;17(5):2497-501
references: 9111318
references: Science. 1994 Jun 3;264(5164):1415-21
references: 8197455
references: J Biol Chem. 1996 Aug 23;271(34):20494-500
references: 8702790
references: Science. 2009 Dec 18;326(5960):1619
references: 20019269
references: Mol Cell Biol. 2006 Nov;26(22):8562-71
references: 16982690
references: Genome Biol. 2004;5(12):253
references: 15575979
references: Cancer Res. 2008 Apr 15;68(8):2920-6
references: 18413761
references: Science. 2002 May 31;296(5573):1653-5
references: 12040185